JP2024518791A - 置換ヘテロ環化合物 - Google Patents

置換ヘテロ環化合物 Download PDF

Info

Publication number
JP2024518791A
JP2024518791A JP2023570177A JP2023570177A JP2024518791A JP 2024518791 A JP2024518791 A JP 2024518791A JP 2023570177 A JP2023570177 A JP 2023570177A JP 2023570177 A JP2023570177 A JP 2023570177A JP 2024518791 A JP2024518791 A JP 2024518791A
Authority
JP
Japan
Prior art keywords
disease
compound
compounds
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518791A5 (https=
Inventor
エイチ スパーゲル,スティーブン
エドワード マーツマン,マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2024518791A publication Critical patent/JP2024518791A/ja
Publication of JP2024518791A5 publication Critical patent/JP2024518791A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023570177A 2021-05-14 2022-05-13 置換ヘテロ環化合物 Pending JP2024518791A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163188498P 2021-05-14 2021-05-14
US63/188,498 2021-05-14
US202263334717P 2022-04-26 2022-04-26
US63/334,717 2022-04-26
PCT/US2022/029118 WO2022241175A1 (en) 2021-05-14 2022-05-13 Substituted heterocyclic compounds

Publications (2)

Publication Number Publication Date
JP2024518791A true JP2024518791A (ja) 2024-05-02
JP2024518791A5 JP2024518791A5 (https=) 2025-05-21

Family

ID=81928066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570177A Pending JP2024518791A (ja) 2021-05-14 2022-05-13 置換ヘテロ環化合物

Country Status (5)

Country Link
US (1) US20240270723A1 (https=)
EP (1) EP4337656A1 (https=)
JP (1) JP2024518791A (https=)
KR (1) KR20240007242A (https=)
WO (1) WO2022241175A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518556A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518555A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518792A (ja) * 2021-05-14 2024-05-02 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492184B2 (en) 2020-12-22 2025-12-09 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
EP4294806A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506369A (ja) * 2012-11-08 2016-03-03 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物
WO2020092196A1 (en) * 2018-10-30 2020-05-07 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
JP2024517453A (ja) * 2021-05-04 2024-04-22 シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド 含窒素複素環ピリジン化合物
JP2024518555A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518556A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518554A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518792A (ja) * 2021-05-14 2024-05-02 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506369A (ja) * 2012-11-08 2016-03-03 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物
WO2020092196A1 (en) * 2018-10-30 2020-05-07 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
JP2024517453A (ja) * 2021-05-04 2024-04-22 シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド 含窒素複素環ピリジン化合物
JP2024518555A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518556A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518554A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518792A (ja) * 2021-05-14 2024-05-02 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
野崎正勝 等, 創薬化学, vol. 第1版, JPN6012059719, 1995, pages 98 - 99, ISSN: 0005834622 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518556A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518555A (ja) * 2021-05-14 2024-05-01 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP2024518792A (ja) * 2021-05-14 2024-05-02 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
JP7818623B2 (ja) 2021-05-14 2026-02-20 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物

Also Published As

Publication number Publication date
EP4337656A1 (en) 2024-03-20
KR20240007242A (ko) 2024-01-16
WO2022241175A1 (en) 2022-11-17
US20240270723A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
JP7490107B2 (ja) スルホンピリジンアルキルアミド置換ヘテロアリール化合物
JP7818623B2 (ja) 置換ヘテロ環化合物
JP6843135B2 (ja) IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なイミダゾピリダジン化合物
JP7097875B2 (ja) Il-12、il-23および/またはifnアルファ応答の調節剤として有用なイミダゾピリダジン化合物
JP2024518791A (ja) 置換ヘテロ環化合物
JP7046092B2 (ja) Il-12、il-23および/またはifnアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物
JP7012082B2 (ja) Il-12、il-23および/またはifn-アルファのイミダゾピリダジン調節剤
JP2024518792A (ja) 置換ヘテロ環化合物
JP2024518556A (ja) 置換ヘテロ環化合物
WO2020159904A1 (en) Amide-disubstituted pyridine or pyridazine compounds
CN117321045A (zh) 经取代的杂环化合物
KR20250099236A (ko) 치환된 헤테로시클릭 화합물
EA047032B1 (ru) Замещенные гетероциклические соединения
CN117355514A (zh) 经取代的杂环化合物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260407